CryoLife Completes Acquisition of JOTEC
ATLANTA, Dec. 1, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable living tissues used in cardiac and vascular surgical procedures. CryoLife markets and sells a highly competitive product portfolio focused on treating aortic disease in more than 80 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
D. Ashley Lee
Executive Vice President, Chief Financial Officer and
|The Ruth Group
View original content with multimedia:http://www.prnewswire.com/news-releases/cryolife-completes-acquisition-of-jotec-300565402.html
SOURCE CryoLife, Inc.